Published in Blood on June 27, 2012
An European Platform for Translational Research in Myelodysplastic Syndromes | NCT04174547
Analysis of Risk in MDS Over Time - Comparison of Treated vs Untreated Patients | NCT04676945
GENOMED4ALL: Improving MDS Classification and Prognosis by AI | NCT04889729
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes. Leukemia (2013) 3.93
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97
Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50
The genetic basis of myelodysplasia and its clinical relevance. Blood (2013) 1.95
Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis. J Clin Oncol (2013) 1.88
SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood (2015) 1.75
Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood (2013) 1.71
Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A (2013) 1.64
Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation. J Clin Oncol (2014) 1.58
An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood (2015) 1.53
Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. Biol Blood Marrow Transplant (2014) 1.43
Biologic and clinical significance of somatic mutations of SF3B1 in myeloid and lymphoid neoplasms. Blood (2012) 1.29
Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica (2012) 1.28
Myelodysplastic syndromes: diagnosis, prognosis, and treatment. Dtsch Arztebl Int (2013) 1.21
Dynamics of ASXL1 mutation and other associated genetic alterations during disease progression in patients with primary myelodysplastic syndrome. Blood Cancer J (2014) 1.18
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry. Leukemia (2015) 1.16
Targeted re-sequencing analysis of 25 genes commonly mutated in myeloid disorders in del(5q) myelodysplastic syndromes. Haematologica (2013) 1.13
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Cancer (2014) 1.08
Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07
Inactivating CUX1 mutations promote tumorigenesis. Nat Genet (2013) 1.06
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood (2016) 1.05
Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. J Clin Oncol (2013) 1.03
Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia (2014) 1.02
Myeloid malignancies with chromosome 5q deletions acquire a dependency on an intrachromosomal NF-κB gene network. Cell Rep (2014) 0.99
There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes. Curr Hematol Malig Rep (2013) 0.98
Morphological classification of the myelodysplastic syndromes: how much more education of diagnosticians is necessary? Haematologica (2013) 0.97
Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol (2014) 0.97
Prognostication in myelodysplastic syndromes: beyond the International Prognostic Scoring System (IPSS). Am J Med (2013) 0.96
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors. Blood (2015) 0.96
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia. Am J Hematol (2013) 0.96
Signal transduction inhibitors in treatment of myelodysplastic syndromes. J Hematol Oncol (2013) 0.95
Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes. Br J Haematol (2013) 0.94
A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res (2014) 0.93
Myelodysplastic syndromes, version 2.2015. J Natl Compr Canc Netw (2015) 0.92
Application of the international prognostic scoring system-revised in therapy-related myelodysplastic syndromes and oligoblastic acute myeloid leukemia. Leukemia (2013) 0.92
Genomic landscape of CD34+ hematopoietic cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad Sci U S A (2014) 0.92
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Am J Hematol (2013) 0.92
Clinical and genetic predictors of prognosis in myelodysplastic syndromes. Haematologica (2014) 0.92
Monosomal karyotype at the time of diagnosis or transplantation predicts outcomes of allogeneic hematopoietic cell transplantation in myelodysplastic syndrome. Biol Blood Marrow Transplant (2015) 0.91
Immunophenotyping in myelodysplastic syndromes can add prognostic information to well-established and new clinical scores. PLoS One (2013) 0.91
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res (2013) 0.90
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes. Clin Cancer Res (2014) 0.90
Evaluation of noncytotoxic DNMT1-depleting therapy in patients with myelodysplastic syndromes. J Clin Invest (2015) 0.90
Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors. Leukemia (2015) 0.90
Beyond hypomethylating agents failure in patients with myelodysplastic syndromes. Curr Opin Hematol (2014) 0.89
Comparison of the prognostic utility of the revised International Prognostic Scoring System and the French Prognostic Scoring System in azacitidine-treated patients with myelodysplastic syndromes. Br J Haematol (2014) 0.89
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes. Am J Hematol (2014) 0.89
Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion. Leukemia (2015) 0.88
Clonal leukemic evolution in myelodysplastic syndromes with TET2 and IDH1/2 mutations. Haematologica (2013) 0.87
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. J Clin Oncol (2016) 0.87
Gain-of-function SAMD9L mutations cause a syndrome of cytopenia, immunodeficiency, MDS, and neurological symptoms. Blood (2017) 0.87
Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clin Geriatr Med (2016) 0.86
Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study. Haematologica (2014) 0.86
CD34 and p53 immunohistochemical stains differentiate hypocellular myelodysplastic syndrome (hMDS) from aplastic anemia and a CD34 immunohistochemical stain provides useful survival information for hMDS. Ann Lab Med (2014) 0.86
Incidence and Burden of the Myelodysplastic Syndromes. Curr Hematol Malig Rep (2015) 0.86
Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome. Rev Bras Hematol Hemoter (2014) 0.85
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. Blood (2016) 0.85
An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies. Blood Cancer J (2015) 0.85
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Am J Hematol (2016) 0.85
Current Role of Genetics in Hematologic Malignancies. Indian J Hematol Blood Transfus (2015) 0.84
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure. Haematologica (2016) 0.84
High concordance of genomic and cytogenetic aberrations between peripheral blood and bone marrow in myelodysplastic syndrome (MDS). Leukemia (2015) 0.84
MDS prognostic scoring systems – past, present, and future. Best Pract Res Clin Haematol (2014) 0.83
CD34-Selected Hematopoietic Stem Cell Transplants Conditioned with Myeloablative Regimens and Antithymocyte Globulin for Advanced Myelodysplastic Syndrome: Limited Graft-versus-Host Disease without Increased Relapse. Biol Blood Marrow Transplant (2015) 0.83
Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer. Expert Opin Investig Drugs (2013) 0.83
The clinical importance of moderate/severe bone marrow fibrosis in patients with therapy-related myelodysplastic syndromes. Ann Hematol (2013) 0.83
Specific abnormalities versus number of abnormalities and cytogenetic scoring systems for outcome prediction after allogeneic hematopoietic SCT for myelodysplastic syndromes. Bone Marrow Transplant (2014) 0.83
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia (2016) 0.83
Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy. Leukemia (2014) 0.82
Oral Azacitidine (CC-486) for the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia. Oncologist (2015) 0.82
Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q). Blood Cancer J (2014) 0.82
Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci (2015) 0.82
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome. Int J Clin Oncol (2013) 0.82
Iron chelation therapy in myelodysplastic syndromes: where do we stand? Expert Rev Hematol (2013) 0.82
SNP Array in Hematopoietic Neoplasms: A Review. Microarrays (Basel) (2015) 0.82
Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise? Oncologist (2015) 0.82
Array CGH identifies copy number changes in 11% of 520 MDS patients with normal karyotype and uncovers prognostically relevant deletions. Leukemia (2015) 0.81
Optimal timing of allogeneic hematopoietic stem cell transplantation in patients with myelodysplastic syndrome. Am J Hematol (2013) 0.81
Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders. Cochrane Database Syst Rev (2015) 0.81
New strategies in myelodysplastic syndromes: application of molecular diagnostics to clinical practice. Clin Cancer Res (2013) 0.81
Myelodysplastic syndromes: what do hospitalists need to know? J Hosp Med (2013) 0.81
Umbilical Cord Blood Transplantation Outcomes in Acute Myelogenous Leukemia/Myelodysplastic Syndrome Patients Aged ≥70 Years. Biol Blood Marrow Transplant (2015) 0.81
Phenotypic and genotypic characterization of azacitidine-sensitive and resistant SKM1 myeloid cell lines. Oncotarget (2014) 0.81
Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classifications. J Hematol Oncol (2016) 0.81
The need for additional genetic markers for myelodysplastic syndrome stratification: what does the future hold for prognostication? Expert Rev Hematol (2013) 0.81
Differences in community and academic practice patterns for newly diagnosed myelodysplastic syndromes (MDS) patients. Cancer Epidemiol (2015) 0.81
Significance of myelodysplastic syndrome-associated somatic variants in the evaluation of patients with pancytopenia and idiopathic cytopenias of undetermined significance. Mod Pathol (2016) 0.81
Translocation (6;15)(q12;q15): A Novel Mutation in a Patient with Therapy-Related Myelodysplastic Syndrome. Case Rep Hematol (2015) 0.80
Total genomic alteration as measured by SNP-array-based molecular karyotyping is predictive of overall survival in a cohort of MDS or AML patients treated with azacitidine. Blood Cancer J (2013) 0.80
Induction of Chromosomal Instability via Telomere Dysfunction and Epigenetic Alterations in Myeloid Neoplasia. Cancers (Basel) (2013) 0.80
Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5). Leukemia (2015) 0.80
Sonic hedgehog produced by bone marrow-derived mesenchymal stromal cells supports cell survival in myelodysplastic syndrome. Stem Cells Int (2015) 0.80
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease. Blood Res (2014) 0.80
Biology of the bone marrow microenvironment and myelodysplastic syndromes. Mol Genet Metab (2015) 0.80
Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med (1996) 46.18
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41
Proposals for the classification of the myelodysplastic syndromes. Br J Haematol (1982) 10.90
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Clonal architecture of secondary acute myeloid leukemia. N Engl J Med (2012) 6.71
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer (2008) 3.75
Impact of the degree of anemia on the outcome of patients with myelodysplastic syndrome and its integration into the WHO classification-based Prognostic Scoring System (WPSS). Haematologica (2011) 3.11
The incidence and impact of thrombocytopenia in myelodysplastic syndromes. Cancer (2007) 2.21
Diagnostic plots to reveal functional form for covariates in multiplicative intensity models. Biometrics (1995) 2.19
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome. Haematologica (2010) 2.14
International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol (2008) 1.99
Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flow cytometry. Blood (2007) 1.92
NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. J Natl Compr Canc Netw (2011) 1.85
Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol (2008) 1.68
The degree of neutropenia has a prognostic impact in low risk myelodysplastic syndrome. Leuk Res (2011) 1.58
Comorbidities and survival in a large cohort of patients with newly diagnosed myelodysplastic syndromes. Leuk Res (2009) 1.57
Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model. J Clin Oncol (2011) 1.55
The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica (2009) 1.46
Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia (1992) 1.45
Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol (2009) 1.43
Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. Leuk Lymphoma (2000) 1.36
Contribution of beta-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS). Blood (2003) 1.31
Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol (2006) 1.27
Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22
Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21
Cytokine targets in the treatment of myelodysplastic syndromes. Curr Hematol Rep (2005) 1.12
Impact of age and comorbidity in myelodysplastic syndromes. J Natl Compr Canc Netw (2008) 1.05
Prognostic impact of severe thrombocytopenia in low-risk myelodysplastic syndrome. Cancer (2011) 0.99
Prognostic significance of serial determinations of lactate dehydrogenase (LDH) in the follow-up of patients with myelodysplastic syndromes. Ann Oncol (2008) 0.98
Prognostic value of lactate dehydrogenase activity in myelodysplastic syndromes. Leuk Res (2001) 0.97
A robust method for proportional hazards regression. Stat Med (1996) 0.96
Levels of beta 2 microglobulin have a prognostic relevance for patients with myelodysplastic syndrome with regard to survival and the risk of transformation into acute myelogenous leukemia. Leuk Res (2008) 0.96
Time changes in predictive power of established and recently proposed clinical, cytogenetical and comorbidity scores for Myelodysplastic Syndromes. Leuk Res (2011) 0.95
Additional prognostic value of bone marrow histology in patients subclassified according to the International Prognostic Scoring System for myelodysplastic syndromes. J Clin Oncol (2003) 0.94
Prognostic factors in myelodysplastic syndromes: critical analysis of the impact of age and gender and failure to identify a very-low-risk group using standard mortality ratio techniques. Br J Haematol (1996) 0.92
Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leuk Res (2011) 0.90
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood (2009) 23.52
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med (2006) 22.86
A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med (2005) 21.48
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol (2003) 17.67
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med (2003) 17.23
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood (2009) 15.95
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med (2006) 13.54
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol (2009) 12.41
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature (2011) 11.44
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med (2003) 11.17
BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature (2008) 10.12
Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med (2011) 9.90
Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med (2013) 9.65
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol (2009) 9.40
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med (2010) 8.77
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer (2006) 8.57
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood (2006) 8.38
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood (2006) 8.33
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol (2005) 7.83
Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med (2004) 7.73
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol (2007) 7.34
Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med (2012) 6.99
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med (2006) 6.90
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2006) 6.89
Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med (2009) 6.67
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol (2009) 6.54
Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood (2013) 6.50
Age and acute myeloid leukemia. Blood (2006) 6.46
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood (2008) 6.39
Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J Clin Oncol (2005) 6.06
New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood (2007) 5.80
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood (2009) 5.72
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med (2013) 5.72
Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet (2002) 5.55
Subnuclear compartmentalization of immunoglobulin loci during lymphocyte development. Science (2002) 5.47
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood (2008) 5.23
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol (2010) 4.72
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol (2010) 4.67
A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med (2007) 4.59
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia. Blood (2010) 4.51
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. N Engl J Med (2011) 4.50
Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1. Nat Genet (2004) 4.45
Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood (2011) 4.43
Genetic alterations activating kinase and cytokine receptor signaling in high-risk acute lymphoblastic leukemia. Cancer Cell (2012) 4.41
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood (2010) 4.33
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis (2005) 4.31
Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood (2008) 4.26
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis (2004) 4.15
Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood (2003) 4.15
Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell (2010) 4.11
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood (2003) 4.07
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol (2005) 4.06
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet (2012) 4.03
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res (2005) 4.00
Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol (2007) 3.99
Mast Cells, Mastocytosis, and Related Disorders. N Engl J Med (2015) 3.90
New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol (2012) 3.88
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood (2011) 3.87
JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood (2013) 3.78
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood (2004) 3.76